Royalty Pharma plc
HealthcareNASDAQ:RPRX · NASDAQ Global Select
-$0.14 today
Vol 1.57M · Avg 3.65M
Intrinsic Value
RPRX Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor RPRX
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when RPRX drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is RPRX cheaper or more expensive than usual?
Review how the market has valued Royalty Pharma plc over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
+59.75%
Period High
$55.87
Period Low
$33.83
Latest
$55.16
Analyst Targets
See where analysts expect RPRX to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$55.16
Low Target
$50.00
Avg Target
$56.67
High Target
$63.00
Upside (Avg)
+2.74%
Alternatives to RPRX
Compare Royalty Pharma plc with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
United Therapeutics Corporation
NASDAQ:UTHR
$23.00B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.79B
Incyte Corporation
NASDAQ:INCY
$21.78B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.37B
Tenet Healthcare Corporation
NYSE:THC
$15.26B
Exelixis, Inc.
NASDAQ:EXEL
$13.39B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.59B
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for RPRX
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | +92.5% | +70.4% |
Revenue | N/A | N/A | -1.1% | +1.1% |
Equity | +11.3% | -2.5% | +1.1% | -3.0% |
Cash | N/A | N/A | -47.2% | -87.2% |
ROIC | 9.4% | 7.1% | 8.4% | 8.9% |
Analysis
Latest growth is strongest in EPS at +70.4% and weakest in Cash at -87.2%. Three-year average ROIC is 8.4%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +92.5% | +1.4% (11yr)1 analysts |
| Revenue | N/A | N/A | -1.1% | +9.6% (11yr)1 analysts |
| Net Income | N/A | N/A | +60.7% | +5.7% (11yr)1 analysts |
| EBIT | N/A | N/A | +53.7% | +1.1% (11yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +92.5% over three years. Forward estimates point to Revenue at +9.6% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.4B of revenue converted into $827.6M of net income for the selected period. Gross margin is 100.0% and net margin is 33.4%, showing how much revenue survives after costs and taxes. EPS is $1.77, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well Royalty Pharma plc turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.9%
avg 17.7%
ROIC
8.9%
avg 9.3%
ROA
3.9%
avg 7.1%
Analysis
ROE is currently the strongest return metric at 11.9% versus its period average of 17.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
1.63%
Buyback Yield (TTM)
2.40%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
4.03%
Analysis
Total TTM shareholder yield is 4.03% including 0.00% from debt paydown. The largest current contributor is buybacks at 2.40%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
1.65%
Annual Div/Share
$0.91
Payout Ratio
46.8%
Frequency
Quarterly
Shareholder Yield
6.77%
Next Ex-Date
Not announced
Next Payment
—
1Y Growth
+5.8%
3Y CAGR
+5.3%
5Y CAGR
+7.3%
Dividend Payments, Annual Total (TTM) & Yield
Analysis
The current indicated dividend yield is 1.65%, with TTM dividends of $0.91 per share. Three-year dividend growth is +5.3%, which helps show whether payouts are compounding or flattening. The payout ratio is 46.8%, so compare payout growth against earnings coverage. Payments are currently quarterly.
Company Overview
Understand how Royalty Pharma plc makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what Royalty Pharma plc does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | $44.02M | — | 63 | $1.24M | 0.29% |
James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | $3.40M | — | 56 | $478,870.00 | 0.11% |
Arthur Richard McGivern | Executive Vice President of Investments & Chief Scientific Officer | $3.40M | — | 51 | $0.00 | <0.01% |
Christopher Hite | Chairman of Partnering & Investments | $1.32M | — | 59 | $709,399.00 | 0.16% |
Terrance Coyne | Executive Vice President & Chief Financial Officer | $1.32M | — | — | $0.00 | <0.01% |
Marshall Urist | Executive Vice President of Research & Investments | $1.32M | — | 50 | $18,197.00 | <0.01% |
Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer | — | — | — | — | — |
Sandy Balkin | Senior Vice President of Strategy & Analytics | — | — | — | — | — |
George Grofik | Senior Vice President and Head of Investor Relations & Communications | — | — | — | $0.00 | <0.01% |
Molly Sawaya | Executive Vice President & Head of Human Capital | — | — | — | — | — |
Sara Klymkowsky | Senior Vice President of Research & Investments | — | — | — | — | — |
Sam Landsberg | Finance and Treasurer | — | — | — | — | — |
Kenneth Siming Sun | Senior VP & Head of Asia | — | — | — | — | — |
Ashwin Pai | Executive Vice President of Investments & Partnering | — | — | — | — | — |
Lucas Glass | Head of Artificial Intelligence | — | — | — | — | — |
Scott Raichilson | Chief Accounting Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
60
$64.55M
Net Sentiment
$64.55M
Net selling
Most Active
Coyne Terrance P.
33 transactions
1–10 of 60
Analysis
Insiders reported 0 buys worth $0.00 and 60 sells worth $64.55M over the last 12 months. That adds up to net selling of $64.55M. Coyne Terrance P. was the most active insider with 33 transactions.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $586.4M |
| Short-term Investments | $21.9M |
| Receivables | $807.4M |
| Other Current | $10.2M |
| Total Current Assets | $1.4B |
| Goodwill | $924.6M |
| Intangible Assets | $16.5B |
| Long-term Investments | $845.8M |
| Other Non-current | $76.8M |
| Total Non-current Assets | $18.4B |
| Total Assets | $19.8B |
Analysis
Selected assets total $19.8B for Latest. The largest visible component is Intangible Assets at $16.5B, about 83.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.